Last updated on November 2018

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)


Brief description of study

This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.

Detailed Study Description

At the end of the study, patients with no clinically significant toxicities, no contraindications to continue treatment with talazoparib, and no disease progression (underlying cancer progression) may be eligible to continue talazoparib treatment in a separate open-label extension study. The decision to allow the patient to continue dosing with talazoparib in an open-label extension (OLE) study will be based on potential overall benefit-risk and patient meeting eligibility criteria for OLE.

Clinical Study Identifier: NCT02997176

Contact Investigators or Research Sites near you

Start Over

Pfizer Pfizer CT.gov Call Center

UCLA Hematology/Oncology - Santa Clarita
Valencia, CA United States
4.11miles
  Connect »